INSERM Research Director, CNRS UMR7260
Dr. Yves Cazals is known to be one of the most famous international expert on pathophysiology and rehabilitation of deafness and tinnitus. He spent the majority of his Research Career looking at cochlear disorders by bridging clinical observations with animal experiments using electrophysiological and histological technics, which are now the references to detect and measure hearing loss and tinnitus in pharmacology. His mentoring to CILcare activity has been absolutely key to put CILcare’s offer at the cutting edge of the scientific progress in translational sciences especially with regards to tinnitus. At the image of an outstanding federator, his circle of partners is not only focused on research in pharmacology but is extended to several other transversal areas, which really gives to the hearing research he is contributing to, the perspectives it deserves. At the end what matters is to bring solutions for people, who suffers from hearing disorders, doesn’t it? We are very proud to have Doctor Cazals part of our Scientific Advisors.
Dr. Richard Salvi
SUNY Distinguished Professor at the University at Buffalo
We are pleased to have Dr. Richard Salvi, SUNY Distinguished Professor at the University at Buffalo as a member of the CILcare advisory team. Dr. Salvi is internationally known for his scientific work on the auditory system and a broad range of hearing disorders. Over the past 40 years, Salvi has published more than 400 papers, books, chapters and scientific reports and has organized more than a dozen international symposia and conferences. His research spans a broad range of topics that include noise-induced hearing loss, ototoxicity, age-related hearing loss, hair cell regeneration, tinnitus, hyperacusis and neural plasticity. His research investigations have involved a diverse range of experimental techniques including animal behavior, electrophysiology, anatomy, genomics, proteomics and brain imaging with humans and animals. Salvi is the Director of the Center of Hearing and Deafness at the State University of New York at Buffalo, a research institute with that focuses on hearing impairments that affect the peripheral and central auditory system. Salvi’s current research interests include: (1) understanding the biological mechanisms underlying hearing loss (2) identifying the neural mechanism contributing to tinnitus and hyperacusis, (3) identifying drugs that can prevent, protect, restore hearing loss or suppress tinnitus, (4) central auditory system plasticity and (5) age-related hearing loss. Salvi will advise CILcare in the selection, set-up and the management of scalable preclinical models of normal hearing and hearing loss and will be accessible to drug developers for their last preclinical steps before moving in clinical trials. Having his experience supporting CILcare is a true honor.
CNRS Research Director, CNRS UMR7260
Arnaud Norena leads the team “Sensory systems and neuroplasticity” of the Neuroscience Department located at Aix-Marseille University (UMR 7260) where he also teaches as a full-time Professor. His work has been focused on understanding auditory function and dysfunction mechanisms for many years with a strong emphasize on tinnitus physiology and psychophysics. He’s recognized all over the world as a key opinion leader in this field. He has developed an influential model of tinnitus which accounts well for many facets of the tinnitus phenomenology (Noreña, 2011; Noreña and Farley, 2012). His innovation is continuously rewarded by national and international agencies and he published nearly 40 papers in the field of auditory neurophysiology and tinnitus .
Dr. Norena is an explorer, who always pushes CILcare’s in-vivo methods in electrophysiology and electroacoustic to the very best. We’re so lucky to have him on board!
President of OCT Consulting
Bernard Bourrié has a Ph.D in macromolecular Biology from the University of Montpellier. He has more than 30 years of experience in academic research and pharmaceutical industry.
Before founding OCT, Bernard led teams and developed animal models, mainly in rodents, to support drug discovery and development at Sanofi in the fields of oncology. He was head of the in vivo pharmacology team in the Oncology group of Sanofi in Montpellier and was in charge of several preclinical programs.
Bernard managed many studies aiming at determining the potential efficacy of new drugs targeting tumors and their metastasis (antibody-drug conjugates, tubulin binders, platinum, kinases inhibitors). He is the author of several international publications and patents.
Bernard also teaches « New R&D strategies in oncology – Cancer personalized medicine » in Medecine and Sciences Universities in France.